All Updates

All Updates

icon
Filter
Partnerships
Inocras and Massive Bio partner for enhanced personalized care in cancer treatment
Clinical Trial Technology
Jun 3, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jun 3, 2024

Inocras and Massive Bio partner for enhanced personalized care in cancer treatment

Partnerships

  • Inocras and Massive Bio have entered a partnership to improve personalized cancer treatment and care.

  • The collaboration involves employing Inocras's whole-genome sequencing (WGS) and bioinformatics expertise with Massive Bio's AI technology for clinical trial matching, which will permit cancer patients to be informed of prospective clinical trials that align with their genetic profile without the need for additional tests. Massive Bio is expected to enhance the scope of trial enrollment by reducing screen failures using its predictive analytics.

  • The alliance aims to increase the benefits of precision medicine for cancer patients and deliver tailored cancer care based on individual genetic profiles.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.